Clinical Trials Browser

Interventional × capivasertib × Genitourinary × Clear all

Prostatic Neoplasms

NCT05593497 2025-04-16

SNARE

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

750 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

1,035 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

12 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

27 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02121639 2022-05-05

ProCAID

Phase 1/2 Completed

160 enrolled

Genitourinary

Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

Phase 1 Completed

11 enrolled

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Clinical Trials

CAPItello-281

SNARE

ProBio

CAPItello280

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

ProCAID

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body